Marie Vanseymortier

Prognostic factors among cancer patients with good performance status screened for phase I trials

Nicolas Penel, Marie Vanseymortier, Marie-Edith Bonneterre et al. · Investigational New Drugs · 2007 · 55 citations

Prognostic Factors, Prognostic Evaluation, Good Performance Status +13

Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery

Houssein El Hajj, Marie Vanseymortier, Delphine Hudry et al. · ESMO Open · 2021 · 27 citations · Full text

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

Thomas Brodowicz, Bernadette Liegl-Atzwager, Emmanuelle Tresch et al. · BMC Cancer · 2015 · 22 citations · Full text

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

Nicolas Penel, Olivier Mir, Jennifer Wallet et al. · European Journal of Cancer · 2020 · 20 citations · Full text

Phase Ii Trial, Medicine, Pharmacology +6

Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients

Audrey Mailliez, Pascal Pigny, Emilie Bogart et al. · International Journal of Cancer · 2022 · 14 citations